METHOD FOR PREDICTION OF ANTIVIRAL THERAPY (AVT) EFFICACY IN CHRONIC HEPATITIS B (CHB) Russian patent published in 2012 - IPC G01N33/49 

FIELD: medicine.

SUBSTANCE: for the purpose of prediction of a virusological reponse in the patients suffering chronic combined HBV/HCV-infection, the antiviral therapy of chronic hepatitis B is associated with measuring the blood serum TNF-α cytokine content prior to and during the therapy on the 4-5th week and on the 7-8th week. If the initial TNF-α cytokine content increased in 1.5 times and more on the 4-5th week of the therapy to be decreased in 1.5 times and more from the initial level on the 7-8^th week of the therapy, a good efficacy of the prescribed therapy is predicted. If the initial increased in 1.5 times and less on the 4-5th week or the TNF-α value decreased in 1.5 times and less from the initial level on the 7-8th week of the therapy, the therapy is predicted to be ineffective.

EFFECT: method allows early prediction of the antiviral therapy effect in the 4-8th weeks from the beginning of the therapy.

2 dwg, 2 ex